Analyst consensus rating
Helus Pharma Analyst Rating: none
Direct answer
Helus Pharma's consensus rating is none.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $40.64.
Forecast evidence checked November 13, 2026.
Get free Helus Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.86
- Average price target
- $40.64
- High price target
- $69.03
- Low price target
- $14.87
- Low target gap
- +67.8%
- Target upside
- +358.7%
- High target gap
- +679.1%
- Target range width
- 611.3%
- Consensus rating
- none
- Analysts
- 10
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Helus Pharma?
Helus Pharma has a verified none consensus. The same dataset has an average price target of $40.64.
How far are Helus Pharma's low and high targets from the recorded price?
The low target implies +67.8%, while the high target implies +679.1%.
How many analysts are included in Helus Pharma's consensus?
The verified consensus includes 10 analysts.
How is Helus Pharma's target upside or downside calculated?
The average target of $40.64 is divided by the recorded price of $8.86, then one is subtracted to produce +358.7%. This does not guarantee a future return.
When was Helus Pharma's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.